Prevention, treatment and cure of HIV infection
RJ Landovitz, H Scott, SG Deeks - Nature Reviews Microbiology, 2023 - nature.com
The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …
has been marked by a series of remarkable successes. However, the efforts to develop a …
Lenacapavir: first approval
J Paik - Drugs, 2022 - Springer
Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus
type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and …
type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and …
FDA-approved fluorinated heterocyclic drugs from 2016 to 2022
The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a
recurrent motif in medicinal chemistry. The combination of these two features is constantly …
recurrent motif in medicinal chemistry. The combination of these two features is constantly …
Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe
D Gökengin, T Noori, A Alemany… - The Lancet Regional …, 2023 - thelancet.com
The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region,
especially in the Central and Eastern subregions, are hindered by healthcare disparities …
especially in the Central and Eastern subregions, are hindered by healthcare disparities …
Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
S Han, Y Lu - European Journal of Medicinal Chemistry, 2023 - Elsevier
Human immunodeficiency virus (HIV) is the etiological agent of acquired immunodeficiency
syndrome (AIDS). Nowadays, FDA has approved over thirty antiretroviral drugs grouped in …
syndrome (AIDS). Nowadays, FDA has approved over thirty antiretroviral drugs grouped in …
Strategies to overcome HIV drug resistance-current and future perspectives
A Temereanca, S Ruta - Frontiers in Microbiology, 2023 - frontiersin.org
The availability of combined antiretroviral therapy (cART) has revolutionized the course of
HIV infection, suppressing HIV viremia, restoring the immune system, and improving the …
HIV infection, suppressing HIV viremia, restoring the immune system, and improving the …
New approved drugs appearing in the pharmaceutical market in 2022 featuring fragments of tailor-made amino acids and fluorine
The strategic fluorination of oxidatively vulnerable sites in bioactive compounds is a
relatively recent, widely used approach allowing us to modulate the stability, bio-absorption …
relatively recent, widely used approach allowing us to modulate the stability, bio-absorption …
Antiretroviral treatment of HIV-2 infection: available drugs, resistance pathways, and promising new compounds
Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2,
accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer …
accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer …
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
O Ogbuagu, S Segal-Maurer, W Ratanasuwan… - The Lancet …, 2023 - thelancet.com
Background Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-
acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety …
acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety …